J&J said that serious adverse events , such as accidents or illnesses, are"an expected part of any clinical study, especially large studies."
J&J's announcement was followed Tuesday afternoon by news that Eli Lilly had also paused a trial of a coronavirus antibody treatment out of safety concerns.The companies' announcements were also a drag on the broader market, said Briefing.com analyst Patrick O'Hare. Travel-related stocks, which are seen as major beneficiaries of a coronavirus vaccine, suffered especially big drops.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: